SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Meta Expands AI Training With Employee Activity Tracking Tools 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
EMERYVILLE, Calif., March 15, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.
| Zogenix Presentation Details | |
| Date: | Wednesday, March 22, 2017 |
| Time: | 2:10 pm Eastern Time / 11:10 am Pacific Time |
| Location: | New York, NY - Westin New York Grand Central Hotel |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
